<DOC>
	<DOCNO>NCT01516996</DOCNO>
	<brief_summary>The purpose study evaluate efficiency safety add nimotuzumab neoadjuvant concurrent chemoradiotherapy treatment patient locoregionally advance squamous cell carcinoma oropharynx hypopharynx .</brief_summary>
	<brief_title>Safety Efficacy Study Nimotuzumab Plus Neoadjuvant Concurrent Chemoradiotherapy Treat Oropharynx Hypopharynx Cancer</brief_title>
	<detailed_description>Locoregionally advanced squamous cell carcinoma head neck ( LA-SCCHN ) pose one complex management challenge . This stage disease still potentially curable , require combined-modality therapy . Recent study show induction chemotherapy（neoadjuvant）reduced 3-year distant relapse rate . Concurrent chemoradiotherapy ( CCRT ) , hand , demonstrate significant consistent benefit local control rate , impact distant failure inconsistent . Nimotuzumab novel EGFR-targeting monoclonal antibody potential.to use single agent radio- chemotherapy sensitizer treatment SCCHN . Thus , investigator conduct randomize , multicenter phaseⅡ study compare efficiency safety add nimotuzumab neoadjuvant CCRT neoadjuvant CCRT treatment patient locoregionally advance squamous cell carcinoma oropharynx hypopharynx .</detailed_description>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Hypopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Informed consent form Histologically confirm locally advance ( stage III IVb ) , squamous cell carcinoma oropharynx hypopharynx The tumor mass measurable Karnofsky performance status ≥70 Life expectancy estimate 6 month Hematologic : WBC≥4×109 /L , plateletes≥100×109 /L , haemoglobin ≥100 g/L； Hepatic : AST/ALT＜1.5 time upper limit normal ( ULN ) ；serum bilirubin &lt; 1.5 time ULN ; Renal : Creatinine＜1.5 time ULN； Known distant metastasis Primary tumor node receive surgery ( except biopsy ) Received anti EGFR monoclonal antibody treatment Previous chemotherapy radiotherapy Participation interventional clinical trial within 1 month Other malignant tumor ( except nonmelanoma skin Cancer carcinoma situ cervix ) History serious allergic allergy History Serious lung heart disease Pregnancy lactation woman , woman suspect pregnancy men willing get pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Neoadjuvant</keyword>
	<keyword>Concurrent Chemoradiotherapy , CCRT</keyword>
	<keyword>Nimotuzumab</keyword>
	<keyword>Locoregionally Advanced Oropharynx</keyword>
	<keyword>Hypopharynx cancer</keyword>
	<keyword>Randomized</keyword>
	<keyword>Multicenter</keyword>
</DOC>